Health utility, a summary measure of quality of life, has not been previously used to compare outcomes among childhood cancer survivors and individuals without a cancer history. We estimated health utility (0, death; 1, perfect health) using the Short Form-6D (SF-6D) in survivors (n ¼ 7105) and siblings of survivors (n ¼ 372) (using the Childhood Cancer Survivor Study cohort) and the general population (n ¼ 12 803) (using the Medical Expenditures Panel Survey). Survivors had statistically significantly lower SF-6D scores than the general population (mean ¼ 0.769, 95% confidence interval [CI] ¼ 0.766 to 0.771, vs mean ¼ 0.809, 95% CI ¼ 0.806 to 0.813, respectively, P < .001, two-sided). Young adult survivors (age 18-29 years) reported scores comparable with general population estimates for people age 40 to 49 years. Among survivors, SF-6D scores were largely determined by number and severity of chronic conditions. No clinically meaningful differences were identified between siblings and the general population (mean ¼ 0.793, 95% CI ¼ 0.782 to 0.805, vs mean ¼ 0.809, 95% CI ¼ 0.806 to 0.813, respectively). This analysis illustrates the importance of chronic conditions on long-term survivor quality of life and provides encouraging results on sibling well-being. Preference-based utilities are informative tools for outcomes research in cancer survivors.
Health utility is a summary measure of health-related quality of life, estimated using preference or desirability for living in a particular state of health compared with other states of health or death. While generally used to calculate quality-adjusted life expectancy in cost-effectiveness studies, utilities also provide informative estimates of quality of life as an outcome (1) . To date, this approach has not been used to quantify the impact of cancer treatment-related toxicity in long-term adult survivors of childhood cancer. Expressed on a standardized scale, in which 0 represents death and 1.0 represents perfect health, utility measures allow comparisons of quality-of-life outcomes between patient groups (eg, cancer patients vs HIV patients) and the general US population.
Over 83% of children diagnosed with cancer today will become five-year survivors (2) . Despite this remarkable achievement, 40% of childhood cancer survivors face disabling, severe or life-threatening conditions that threaten to undermine their initial cancer success (3) . The burden of childhood cancer may also impact siblings who experience emotional distress and diminished parental attention because of caregiving demands (4) . Better quantifying the impact of treatment-related toxicity can help identify high-risk groups for interventions that may improve survivor health and well-being, as well as inform the treatment choices for newly diagnosed children.
We estimated health utility scores for childhood cancer survivor (n ¼ 7105) and sibling (n ¼ 372) participants in the Childhood Cancer Survivor Study (CCSS) and used the Medical Expenditures Panel Survey (MEPS) as the population comparator (n ¼ 12 803). The CCSS is a multi-institutional, retrospective cohort of more than 14 000 five-year survivors of childhood cancer diagnosed before the age of 21 years between 1970 and 1986 and approximately 4000 siblings (5-8); the cohort is followed prospectively to document the development of largely self-reported chronic conditions. MEPS is a nationally representative survey of the US noninstitutionalized civilian population age 18 years and older (see Supplementary Materials, available online, for additional details) (9) . Both the CCSS and MEPS collected health status data in 2003 that allowed for the calculation of health utilities via a common metric, the Short Form-6D (SF-6D) (10, 11) .
We estimated SF-6D utilities for the entire survivor and sibling samples and within sex-and age-specific groups. Among the survivors, we estimated utilities within each original cancer diagnosis group by treatment exposure and by chronic conditions reported in follow-up. Chronic conditions were classified by severity using the Common Terminology Criteria for Adverse Events (CTCAE version 4.03) (12) . We assessed differences in health utility across groups by comparing mean values (using Welch's two-sided t test) and used multivariable linear regression based on a stepwise selection approach to determine the influence of original cancer, treatment, and chronic condition characteristics (using the F-test). Because the large sample size of the CCSS and MEPS can influence statistical significance, we focused on identifying differences in utility scores that were both statistically significant and clinically meaningful to patients (13) . We considered P values of .05 or less to be statistically significant and, based on published results among several patient groups (14, 15) , defined a minimally important difference (MID) as a .03-point difference in SF-6D score. Statistical analyses were performed in SAS 9.3 (SAS Institute, Cary, NC).
We restricted the analysis to individuals age 18 to 49 years at the time of the health status survey. The MEPS sample consisted of 12 803 individuals, and the CCSS included 7105 survivors and 372 siblings (Supplementary Table 1 Table 2 , available online). However, SF-6D scores did vary by the number and severity of chronic conditions reported (Table 2) . Survivors who reported no conditions had SF-6D scores comparable with general population estimates (mean ¼ 0.809, 95% CI ¼ 0.804 to 0.815, vs mean ¼ 0.809, 95% CI ¼ 0.806 to 0.813, respectively, P ¼ .99). In contrast, compared with those who reported no conditions, SF-6D scores reached MID and were statistically significantly lower in survivors who reported two or more conditions (P < .001). Survivors with multiple severe, disabling or life-threatening conditions (CTCAE grades 3 or 4) had even greater decrements compared with the general population (see also Supplementary Figure 1 , available online). Multivariable models found that older attained age, female sex, and number of chronic conditions were associated with statistically significant SF-6D score decrements (P < .003) (Supplementary Table 3 and Supplementary Figure 2 , available online).
Using the CCSS cohort, the current analysis documents that chronic conditions substantially and negatively affect the quality of life of adult survivors of childhood cancer. In particular, the number and severity of chronic conditions are largely responsible for poor health-related quality of life as estimated with utility scores, not original cancer diagnosis or treatment. Moreover, our analysis shows that younger survivors (age 18-29 years) report a quality of life comparable with general population individuals who are approximately two decades older, adding to the growing evidence that survivors experience accelerated aging because of chronic conditions (17) . Our findings are encouraging for the 20% of survivors who reported no chronic conditions, as well as for siblings of childhood cancer survivors; both groups' utility scores were similar to those from the general population. Limitations to our study include that chronic conditions in the CCSS were self-reported, although estimated SF-6D scores reflect quality of life decrements that may be associated with undiagnosed or unreported conditions. Additionally, the MEPS comparison group includes participants with and without chronic conditions prevalent in the general population (hypertension, heart disease, high cholesterol, emphysema, chronic bronchitis, diabetes, cancer, arthritis, or stroke). However, if we restrict the comparison to include only MEPS participants and survivors with any chronic condition, SF-6D scores were similar (mean ¼ 0.758, 95% CI ¼ 0.752 to 0.765, vs mean ¼ 0.758, 95% CI ¼ 0.755 to 0.762, respectively, P ¼ .99), providing further support that cancer survivorship itself is not associated with quality-of-life decrements. As with all utility measures, the SF-6D may not fully capture the entirety of well-being (18) . We defined the MID based on criteria established by individuals without a cancer history (14, 15) ; survivors may view smaller (or larger) differences to be clinically meaningful.
Our findings, which represent the first use of utility scores to illuminate quality-of-life differences among adult survivors of childhood cancer and nonsurvivors, highlight the importance of chronic conditions on health-related quality of life for childhood cancer survivors and provide encouraging results on the impact of the cancer experience on long-term sibling wellbeing. Use of utility scores may provide a novel framework for clinicians and researchers engaged in pediatric cancer treatment and trials as they consider therapy choices for childhood cancer.
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